Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 8.8% – Time to Sell?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares fell 8.8% during trading on Friday . The stock traded as low as $6.95 and last traded at $6.75. Approximately 24,788 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 33,360 shares. The stock had previously closed at $7.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, HC Wainwright increased their target price on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus target price of $247.50.

Enlivex Therapeutics Stock Down 11.8%

The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -11.86 and a beta of 1.52. The business’s fifty day moving average is $10.26 and its two-hundred day moving average is $13.23.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter valued at $33,000. Invesco Ltd. acquired a new position in shares of Enlivex Therapeutics during the fourth quarter valued at $43,000. XTX Topco Ltd lifted its stake in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after acquiring an additional 19,132 shares during the period. Jane Street Group LLC boosted its holdings in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after acquiring an additional 52,553 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in Enlivex Therapeutics in the third quarter valued at about $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.